(Q24188051)

3

0 references

Sophia Zoungas

5

0 references

Alan Cass

7

Alan Cass

0 references

Giovanni Strippoli

10

Giovanni FM Strippoli

0 references

Sankar Navaneethan

6

Sankar D Navaneethan

0 references

Toshiharu Ninomiya

9

Toshiharu Ninomiya

0 references

Meg Jardine

11

Meg J Jardine

0 references

Sagar U Nigwekar

2

Sagar U Nigwekar

0 references

Amy Kang

1

Amy Kang

0 references

Satyarth Kulshrestha

4

Satyarth Kulshrestha

0 references

author name string

Martin P Gallagher

Cochrane Database of Systematic Reviews

8

0 references

publication date

4 May 2015

0 references

published in

0 references

cites work

Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Physical rehabilitation and risk of atherosclerosis after successful kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

The effect of garlic on hypercholesterolemia in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effect of folic acid therapy on serum homocysteine level in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Treatment of hyperhomocysteinemia and endothelial dysfunction in renal transplant recipients with B vitamins in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Homocysteine lowering and cardiovascular events after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Folic acid food fortification-its history, effect, concerns, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Cyclosporine withdrawal improves long-term graft survival in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Should folic acid fortification be mandatory? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Homocysteine lowering with folic acid and B vitamins in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Classical homocystinuria: vascular risk and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Interventions for lowering plasma homocysteine levels in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

Effects of folic acid fortification on spina bifida prevalence in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Homocysteine and vascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Treatment of hyperhomocysteinemia in end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Folic acid and B vitamins improve hyperhomocysteinemia-induced cardiovascular risk profile in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Folate supplementation fails to affect vascular function and carotid artery intima media thickness in cyclosporin A-treated renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021

Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007910.PUB2

7 January 2021